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Abstract Here we report the molecular cloning of the chicken
(Gallus gallus) neuropeptide Y (NPY) receptor Y2, the first non-
mammalian Y2 receptor. It displays 75^80% identity to
mammalian Y2 and has a surprisingly divergent cytoplasmic
tail. Expression of the receptor protein in a cell line showed that
the receptor did not bind the mammalian Y2 selective antagonist
BIIE0246. Furthermore, porcine [Leu31, Pro34]NPY, which binds
poorly to mammalian Y2, exhibited an unexpectedly high affinity
for chicken Y2. In situ hybridisation revealed expression in the
hippocampus. Thus, the chicken Y2 receptor exhibits substantial
differences with regard to sequence and pharmacological profile
in comparison to mammalian Y2 receptors, while the expression
pattern in the central nervous system resembles that observed in
mammals. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The neuropeptide Y (NPY) family of peptides consists in
tetrapods of NPY, peptide YY (PYY) and pancreatic poly-
peptide (PP). NPY and PYY show a high degree of sequence
identity and are found in all vertebrates [1]. The physiological
e¡ects of the peptides are mediated through receptors belong-
ing to the G-protein coupled receptor superfamily. So far, ¢ve
receptor subtypes have been cloned in mammals [2,3].
The Y1, Y2 and Y5 genes are localised on the same chro-
mosome in human HSA4 [4,5] and pig SSC8 [6] suggesting,
together with the low degree of identity, 30% at the amino
acid level, that these subtypes resulted from ancient local du-
plications early in vertebrate evolution. Subtypes Y4 and y6
are found on human chromosome HSA10 and 5, respectively,
and are approximately 50% identical to Y1 and each other.
These genes presumably arose by duplication of the chromo-
some harbouring the Y1 gene [6], as well as Y2 and Y5 whose
duplicates were probably lost. Indeed, the human genome has
several segments that signify early chromosome or genome
duplications [7]. Thus, Y1, Y4 and y6 form a subfamily within
the NPY receptor family. The ¢ve subtypes di¡er extensively
in their replacement rates as shown by comparisons across
orders of mammals. Y1 and Y2 are the most highly conserved
(each has 95% identity) whereas Y4 and y6 evolve quite rap-
idly (75^85% identity) [6]. Y5 is intermediate; however, its
variability is mostly restricted to the large third cytoplasmic
loop [6].
The physiological e¡ects of the NPY family of peptides are
diverse. The stimulation of appetite, regulation of circadian
rhythm and blood pressure and inhibition of anxiety are
among the most prominent [8,9]. Certain e¡ects are believed
to be mediated primarily by the Y2 receptor subtype, includ-
ing regulation of circadian rhythms, inhibition of presynaptic
transmitter release in the central nervous system as well as the
peripheral nervous system, modi¢cation of the electrophysio-
logical properties of hippocampal neurons, nasal congestion
and gastro-intestinal and renal epithelial secretion [10^12].
NPY has been shown to bind to all Y receptors, albeit with
low a⁄nity to Y4. PYY binds to, and can mimic the actions
of, NPY on all subtypes except Y3 [13], which has not yet
been cloned. The mammalian Y2 receptors exhibit the same
pharmacological pro¢le binding both NPY and PYY and a
number of truncated NPY analogues as well as the Y2 selec-
tive antagonist BIIE0246. None of the previously character-
ised Y2 receptors bind endogenous PP from rat (r) and hu-
man (h), or the modi¢ed NPY analogue porcine (p) [Leu31,
Pro34]NPY, which have therefore been used to di¡erentiate
between the Y2 and other NPY receptor subtypes [14^16].
The complexity and diversity of the biological actions of the
NPY family of peptides and their receptors is not fully under-
stood. Characterisation of the receptors in more distantly re-
lated species may help resolve both the evolution of the re-
ceptor^peptide system and the primary physiological
functions, as well as assist in generating further sequence in-
formation in order to clone and characterise receptor subtypes
in other more primitive vertebrate species.
The present study describes a chicken (ch) clone encoding a
Y2 receptor. We present here the sequence, anatomical
mRNA distribution, as well as the pharmacological pro¢le
using a number of analogues, fragments and derivatives of
NPY.
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2. Materials and methods
2.1. Screening of genomic library
Approximately 700 000 clones representing roughly four genome
equivalents from a library in the vector EMBL3 were screened using
two polymerase chain reaction (PCR) generated 32P-labelled full
length Y2 fragments from rat and human. Hybridisation was carried
out at 42‡C in 25% formamide, 6USSC, 10% dextran sulphate,
5UDenhardt’s solution and 0.1% SDS over night. The ¢lters were
washed twice in 2USSC/0.1% SDS at room temperature for 5 min,
and twice in 0.5USSC/0.1% SDS for 30 min at 42‡C. One clone
hybridising to two duplicate ¢lters was selected and digested using
EcoRI. Southern blot and subsequent hybridisation with the human
and rat Y2 probes revealed two bands with sequence homology to the
probe fragments. A 2.1 kb fragment containing 800 bp of the chY2
gene was cloned in pBluescript KS+vector and sequenced. DNA prep-
arations from the selected phage clone were sequenced using speci¢c
sequencing probes designed from the cloned fragment. Primers were
then designed in order to obtain a full length sequence.
2.2. DNA sequencing and amino acid alignment
Sequence determinations were performed using ABI PRISM Dye
Terminator cycle sequencing kit according to the manufacturer’s di-
rections (Perkin Elmer) and analysed by an automated ABI-310 £uo-
rescent-dye sequencer (Applied Biosystems). Sequence alignments
were performed using Lasergene DNASTAR Megalign software.
Transmembrane regions were based upon Schwartz et al. [17]. A se-
quence distance tree was made using alignments with Y2, Y1 and Y5
sequences and, as an outgroup, bradykinin B1 and B2 receptor amino
acid sequences retrieved from GenBank.
2.3. Cloning in expression vector
A fragment containing the entire coding region of the chY2 gene
was generated with Platinum Pfx DNA polymerase (Gibco BRL),
using speci¢c primers containing EcoRI and BamHI sites. Cycle:
20 s at 95‡C, 30 s at 50‡C and 1 min 20 s at 68‡C for 35 cycles.
The PCR fragment was puri¢ed by Qiagen PCR product puri¢cation
kit (Qiagen), digested using EcoRI and BamHI. The 1.2 kb fragment
was then puri¢ed with QIAquick PCR puri¢cation kit (Qiagen) and
then ligated into a pTEJ8 expression vector to give the clone chY2-
pTEJ8. The construct was sequenced and found to be identical to the
genomic clone.
2.4. Transfection protocol
For transient transfections HEK293 (EBNA) cells were transfected
with the construct chY2-pTEJ8 using FuGENE1 Transfection Re-
agent (Boehringer Mannheim, Germany), diluted in OptiMEM me-
dium (Gibco BRL, Stockholm, Sweden) according to the manufactur-
er’s recommendations. After transfection, cells were grown in
Dulbecco’s modi¢ed Eagle’s medium (DMEM)/Nut Mix F-12 w/o
L-glutamine (Gibco BRL) containing 10% foetal calf serum (Biotech
Line AS, CA, USA), 24 mM L-glutamine (Gibco BRL) and 250 Wg/ml
G-418 (Gibco BRL), penicillin^streptomycin (100 U penicillin, 100 Wg
streptomycin/ml) (Gibco BRL) until harvesting by centrifugation,
after 48 h. Cell membrane pellets were frozen in aliquots at 380‡C.
To obtain semi-stable cells for studies of cyclic AMP (cAMP),
HEK293 (EBNA) cells were grown in DMEM containing 10% foetal
calf serum and 250 Wg/ml G-418. Cells were transfected with 6 Wl
FuGENE1 and 2 Wg of the construct chY2FLAG-pCEP4 (which
contains the nine amino acid FLAG epitope in the very carboxy
terminus). After 24 h, the cells were split and 400 Wg/ml hygromycin
B (Gibco BRL) was added to the medium. A control plate with un-
transfected cells was treated the same way and after 7 days all cells in
the control plate were dead while the transfected plate was con£uent.
The cells from the transfected plate were grown under hygromycin
selection and subsequently checked for 125I-pPYY binding. The phar-
macology of the stably expressed chY2 receptor was indistinguishable
from that of the transiently expressed receptor reported in this paper.
2.5. Peptides and peptidic and non-peptidic antagonists
Porcine NPY, p[Leu31, Pro34]NPY, pNPY2^36, pNPY3^36,
pNPY18^36, hPP and rPP were purchased from Bachem, King of
Prussia, PA, USA; p[D-Trp32]NPY from Peninsula Laboratories,
CA, USA. BIBP3226 [18] was synthesised at Dr. Karl Thomae’s lab-
oratories. SR120819A [19] was provided by Sano¢, chicken PP and
PYY were purchased from Schafer-N, Copenhagen, Denmark. Non-
peptidic Y2 antagonist BIIE0246 [20] was provided by Boehringer-
Ingelheim PharmaKG, Biberach an der Riss, Germany.
2.6. Binding assays
The thawed aliquots of membranes were resuspended in 25 mM
HEPES-bu¡er (pH 7.4) containing 2.5 mM CaCl2, 1 mM MgCl2
and 2 g/l bacitracin and homogenised using an Ultra-Turrax homog-
eniser. Saturation experiments were performed in a ¢nal volume of
100 Wl with 4^5 Wg protein and 125I-pPYY (Amersham, UK) for 2 h at
room temperature. This radioligand is iodinated at tyrosines 21 and
27 and has a speci¢c activity of 4000 Ci/mmol. Saturation experiments
were carried out with serial dilutions of radioligand. Non-speci¢c
binding was de¢ned as the amount of radioactivity remaining bound
to the cell homogenate after incubation in the presence of 100 nM
unlabelled pNPY. Competition experiments were performed in a ¢nal
volume of 100 Wl. Various concentrations of the peptides pNPY, hPP,
rPP, chPP, chPYY, p[Leu31, Pro34]NPY, pNPY2^36, pNPY3^36,
pNPY13^36, pNPY18^36, p[D-Trp32]NPY, two non-peptidic Y1 an-
tagonists SR120819A and BIBP3226, and one non-peptidic Y2 antag-
onist BIIE0246 were included in the incubation mixture along with
125I-pPYY. Incubations were terminated by ¢ltration through GF/C
¢lters, Filtermat A (Wallac Oy, Turku, Finland), that had been pre-
soaked in 0.3% polyethyleneimine, using a TOMTEC (Orange, CT,
USA) cell harvester. The ¢lters were washed with 5 ml of 50 mM Tris
(pH 7.4) at 4‡C and dried at 60‡C. The dried ¢lters were treated with
MeltiLex A (Wallac) melt-on scintillator sheets and the radioactivity
retained on the ¢lters counted using the Wallac 1450 Microbeta coun-
ter. The results were analysed using the Prism 2.0 software package
(Graphpad, San Diego, CA, USA). Protein concentrations were mea-
sured using a Bio-Rad Protein Assay (Bio-Rad, Solna, Sweden) with
bovine serum albumin as standard.
2.7. Inhibition of forskolin stimulated cAMP synthesis
Cyclic AMP was assayed on stably transfected HEK293 (EBNA)
cells. The cells were detached by pipetting with media, diluted to 1000
cells/Wl and treated for 30 min at 37‡C with 250 WM isobutylmethyl-
xanthine (Sigma). About 200 000 cells (200 Wl) were incubated with
10 WM forskolin (Sigma) and various concentrations of chPYY,
pNPY, p[Leu31, Pro34]NPY, pNPY2^36, or pNPY18^36 for 20 min
at 37‡C in a total volume of 250 Wl. The ability of BIIE0246 to inhibit
the e¡ect of 100 nM pNPY was also tested. Reactions were termi-
nated by adding 25 Wl HClO4 (4.4 M) and the suspension was neu-
tralised by adding 40 Wl KOH (5 M). Membranes were pelleted by
centrifugation and 50 Wl of the supernatant was used to quantify
cAMP with a radioassay using 3H-cAMP (Amersham Pharmacia Bio-
tech) as a competitor. After 2 h, bound 3H-cAMP was separated from
free by the addition of 150 Wl of a 1% charcoal suspension (50 mM
Tris, 4 mM EDTA). The tubes were vortexed and spun at maximum
speed for 2 min, 300 Wl of the supernatant was rapidly removed and
counted in a liquid scintillation analyser (Packard). Cyclic AMP bind-
ing protein was extracted from the bovine adrenal cortex.
2.8. In situ hybridisation
Brains from four Bantam chickens (two male, two female; Roslin
Institute £ock) were processed for in situ hybridisation. The birds
were maintained on a photoperiod of 14L10D and had free access
to food and water. Brains were rapidly dissected from birds killed by
cervical dislocation and were immediately frozen in powdered dry ice.
The tissue was stored at 370‡C before being sectioned on a cryostat
(Shandon, Model OT) at 15 Wm thickness. Coronal sections were
thaw-mounted onto microscope slides (Superfrost Plus, Cellpath,
Hemel Hempstead, Herts, UK) and stored at 370‡C. Slides bearing
brain sections were processed by sequential immersion at room tem-
perature in: 4% paraformaldehyde (5 min); twice in 0.1 M sodium
phosphate (5 min each); water (6 5 s); 0.1 M triethanolamine, pH 8.0
(TEA, 6 5 s); 0.15 M acetic anhydride in 0.1 M TEA (10 min);
2USSC; 70, 95 and 100% ethanol (3 min each); and blow-dried.
Slides were then stored at room temperature until application of the
hybridisation solution. A mixture of two oligonucleotide probes com-
plementary to chicken Y2 receptor mRNA was used for in situ
hybridisation. The oligonucleotide sequences were: 5PCGATCACC-
CCCAACAGAATAATGGAACAGTAAGCAAAGATGAGGAT-3P
and 5PCTGATACGCTTAGAGATTTTGCTTTCCAAGTGATAGA-
CAATACCACGAT-3P. The probes were labelled at the 3P end with
[35S]dATP using terminal deoxynucleotidyl transferase (Amersham,
FEBS 24268 6-11-00
E. Salaneck et al./FEBS Letters 484 (2000) 229^234230
Little Chalfont, Bucks, UK) and were puri¢ed through QIAquick spin
columns (Qiagen, Crawley, West Sussex, UK). Speci¢c activity of the
probes was 108 cpm/Wg oligonucleotide. Hybridisation bu¡er con-
sisted of 50% formamide, 4USSC, 10% dextran sulphate, 1% N-laur-
ylsarcosine, 1UDenhardt’s solution, 200 mM dithiothreitol, and
0.1 mg/ml yeast tRNA. A 100 Wl aliquot of hybridisation solution
containing 3 ng of each labelled probe was applied to each section
and covered with a Para¢lm coverslip. Control sections received hy-
bridisation solution containing a 100-fold excess of each unlabelled
probe. Hybridisation was performed for at least 16 h in humidi¢ed
boxes at 42‡C. After hybridisation, the sections were washed (4U45
min) in 1USSC at 56‡C, and brought to room temperature while in
the ¢nal wash. The tissue was then dehydrated through graded alco-
hols and apposed to Kodak Biomax MR ¢lm for 2^3 weeks at room
temperature. Films were developed using an automatic processor (X-
ograph Imaging Systems, Tetbury, Gloucestershire, UK).
3. Results
A chicken genomic phage library was screened using two
full length Y2 PCR products, human Y2 and rat Y2, under
low stringency conditions. A strongly hybridising clone was
isolated and an 800 bp fragment isolated from the phage was
subcloned in order to obtain a partial length chicken Y2
product. The fragment was sequenced and used to design
primers with which the phage clone was sequenced by se-
quence primer walking.
The open reading frame encodes a protein of 385 amino
acid residues which displays the characteristic features of a
G-protein coupled receptor, i.e. seven putative transmem-
brane regions, a cysteine pair linking extracellular loop 1
and loop 2, and a cysteine in the carboxy terminal tail where
palmitoylation could serve as an anchor to the membrane and
form a pseudo fourth loop (Fig. 1). The receptor also contains
an asparagine residue close to the amino terminal, which has
been identi¢ed as a putative glycosylation site in mammalian
Y2 receptors. The protein has 78^79% identity to the human,
murine, porcine and bovine Y2 receptors and 75% identity to
the guinea pig Y2 subtypes. The mammalian subtypes share
90^94% identity between each other. When compared to other
NPY receptor subtypes the chicken Y2 receptor exhibits con-
Fig. 2. Distance tree for the characterised NPY Y2 receptors, three
Y5 and three Y1 receptors. Branch lengths correspond to sequence
divergence using the neighbour joining method of the Lasergene
DNASTAR Megalign software. The human bradykinin B1 and B2
receptors were used as outgroup to root the tree.F
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siderably less identity: 23^26% to Y1, Y4, Y5 and y6 subtypes
in mammals (Fig. 2). The alignment reveals that divergence to
mammalian Y2 has primarily occurred in the carboxy and
amino terminals while the receptor is more highly conserved
in the transmembrane and loop domains. The genomic clone
described here was found to be intronless in the coding region
as is the case for the Y2 genes in mammals.
The coding sequence of the genomic clone was transferred
to the expression vector pTEJ8 [21] and control sequenced.
The chY2-pTEJ8 construct was transfected into HEK293
(EBNA) cells and membranes prepared from the transfected
cells were then used for radioligand binding assays. The mem-
brane fraction exhibited concentration dependent binding of
125I-pPYY with an a⁄nity constant (Kd) of 25.6 pM
(S.E.M. = 1.7, N = 3) and a Bmax of 303 fmol/mg protein
(S.E.M. = 68, N = 3) (Fig. 3). All tested NPY variants,
pNPY and chPYY were potent inhibitors of 125I-pPYY. The
inhibition constants (Ki) are presented in Table 1. Weak inhi-
bition was seen with p[D-Trp32]NPY (Ki = 400 nM) and no
inhibition was detected with the Y1 antagonists BIBP3226
and SR120819A, rPP, hPP or the Y2 antagonist BIIE0246
(Kis 1 WM). Functional coupling to G-proteins was shown
by inhibition of cAMP synthesis. Chicken PYY
(pEC50 = 9.12 þ 0.09, n = 6), pNPY (9.02 þ 0.18, n = 5), and
pNPY2^36 (8.95 þ 0.28, n = 3) were equally potent while
NPY18^36 (8.27 þ 0.40, n = 5) and p[Leu31, Pro34]NPY
(8.27 þ 0.21, n = 5) were about four-fold less potent (Fig. 4).
The Y2 antagonist BIIE0246 up to a concentration of 1 WM
did not a¡ect the inhibition from 100 nM pNPY (data not
shown).
In situ hybridisation with oligonucleotide probes to the
chicken Y2 receptor revealed a prominent signal in the hippo-
campus (Fig. 5a). No signal was observed in this region after
competition with excess unlabelled probe (Fig. 5b).
4. Discussion
NPY receptors previously cloned in species from several
orders of mammals have revealed that the rates of evolution
di¡er considerably between subtypes [6]. To obtain a greater
understanding of the evolution of the NPY receptor gene
family, and the function of the Y2 subtype in particular, we
have undertaken the molecular cloning of a non-mammalian
Y2 receptor. The chicken Y2 receptor described in this paper
exhibits 75^80% identity with mammalian Y2 sequences,
which is in agreement with the 90^95% identity between mam-
mals and further supports that it is a well conserved receptor
(Fig. 1).
A higher degree of identity was seen within the postulated
transmembrane regions, whereas some divergence can be seen
in the loop regions, and particularly in the amino and carboxy
termini. In addition to the DRH motif located at the carboxy
terminal end of the third transmembrane region typical for
NPY Y2 subtypes, the amino acid translation reveals con-
served postulated structurally important amino acids for di-
sulphide bridges, palmitoylation and glycosylation [1]. A phy-
logenetic tree with other NPY receptor sequences places the
chicken Y2 sequence closest to the mammalian Y2 sequences,
and at a substantial distance from the other receptor subtypes
(Fig. 2).
Cloning into a eukaryotic expression vector allowed us to
express the receptor gene in a mammalian cell line. A wide
variety of peptides, truncated peptides and analogues were
used to determine the pharmacological pro¢le in competition
with iodinated pPYY. The properties proved to be deviant
Fig. 3. Saturation binding isotherm and Scatchard (inset) analyses
of 125I-pPYY binding to membranes prepared from HEK293
(EBNA) cells transfected with the chY2 expression plasmid chY2-
pTEJ8. The ¢gure shows results from a representative experiment.
Table 1
Inhibition of 125I-pPYY binding to membranes from HEK293
(EBNA) cells transfected with the chY2-pTEJ8 expression construct
using NPY, truncated NPY peptides and non-peptide analogues
Ligand pKI (3log M) S.E.M. n
chPYY 9.20 0.08 3
pNPY 9.46 0.06 3
pNPY2^36 9.26 0.06 3
pNPY3^36 9.13 0.06 3
pNPY13^36 8.91 0.08 3
pNPY18^36 7.70 0.10 3
[Leu31, Pro34]NPY 8.25 0.05 3
rPP 6 6.0 3
hPP 6 6.0 3
chPP 6 6.0 3
BIBP3226 6 6.0 3
SR120819A 6 6.0 3
p[D-Trp32]NPY 6.42 0.11 3
BIIE0246 6.20 0.06 3
Fig. 4. Inhibition of forskolin stimulated cAMP synthesis. Baseline
represents unstimulated cells and 100% represents cells after stimula-
tion of 10 WM forskolin. The ¢gure shows one representative experi-
ment.
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from previously characterised Y2 receptors [15,16,22^24], with
the following binding in rank order of potency: pNPY = ch-
PYY = pNPY2^36 = pNPY3^36s pNPY13^36s pNPY18^3-
6 = p[Leu31, Pro34]NPYDp[D-Trp32]NPY (Table 1). No bind-
ing (Kis 1 WM) was observed for BIBP3226, SR120819A,
rPP, hPP and BIIE0246. Two of the tested ligands displayed
binding a⁄nities that di¡er considerably from known interac-
tions with mammalian Y2 receptors: BIIE0246, a potent an-
tagonist at the human [20], rat [25] and guinea pig [26] Y2
receptors, did not exhibit speci¢c binding at the chY2 recep-
tor; and p[Leu31, Pro34]NPY that does not bind to previously
characterised Y2 receptors, e.g. Ki6 1 WM, binds to the chY2
receptor with relatively high a⁄nity. Functional coupling to
G-proteins was also studied. Chicken PYY, pNPY and
pNPY2^36 inhibited cAMP synthesis in stably transfected
HEK293 (EBNA) cells with EC50 values of about 1 nM
(Fig. 4). The truncated peptide pNPY18^36 displayed an
EC50 of 5 nM, i.e. four times higher than the Ki value. Inter-
estingly, p[Leu31, Pro34]NPY was also a full agonist only ¢ve-
fold less potent than chPYY. BIIE0246 did not inhibit the
e¡ect of 100 nM pNPY in agreement with the competition
studies. The similarity of chY2 to mammalian Y2 in the abil-
ity to inhibit cAMP synthesis indicates that the divergent car-
boxy terminal tail does not alter the interaction with Gi pro-
teins.
The p[Leu31, Pro34]NPY peptide does not bind to any of
the known mammalian Y2 receptors. It was designed to be
more similar to the mammalian PP [27] that primarily binds
to the NPY Y4 subtype [28]. In p[Leu31, Pro34]NPY the Glu34
residue of mammalian NPY has been replaced by a proline
residue found at the corresponding position of all mammalian
PP sequences. This gives the peptide a higher a⁄nity for the
mammalian Y4 subtype, i.e. the PP receptor [28]. Chicken PP,
as well as other known avian PP sequences, di¡ers from the
mammalian PP peptides by having a histidine at position 34
[1]. This di¡erence may explain why the avian Y2 receptor
would not have the need to discriminate against the Pro34
residue in the p[Leu31, Pro34]NPY analogue. This reveals an
important di¡erence between the avian and mammalian NPY
peptide^receptor interactions, which should prove useful for
mutagenesis studies.
A molecular explanation for the lack of binding of the
BIIE0246 antagonist cannot yet be given, but considering
the evolutionary distance between the mammalian and avian
lineages, and the fact that BIIE0246 was designed to bind to
the human and rat Y2 receptors [20] this is not unexpected.
Fig. 5. In situ hybridisation of 35S end-labelled oligonucleotides to chicken NPY Y2 receptor mRNA in chicken brain sections. A speci¢c hy-
bridisation signal in the hippocampus (Hp) (a) disappears in an adjacent section after competition with an unlabelled oligonucleotide probe (b)
while non-speci¢c hybridisation to the optic chiasm and neural tracts is retained. Scale bar = 2 mm.
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Unfortunately, this means that BIIE0246 cannot be used in
functional studies in chicken. The sequence of the chY2 re-
ceptor may prove to be of great value when investigating
binding sites for BIIE0246 at the human Y2 receptor by
site-directed mutagenesis, and such experiments are in prog-
ress.
Although the amino acid sequence and pharmacological
properties of the chicken Y2 receptor di¡er signi¢cantly
from its mammalian counterparts, the localisation of the re-
ceptor to the hippocampus in the present study (Fig. 5) in-
dicates that the neuroanatomical distribution is conserved be-
tween birds and mammals. Expression of the Y2 receptor in
the hippocampus is consistently reported in mammalian spe-
cies including rat [29,30], sheep [31] and human [32]. The
expression of NPY receptors in the chicken hippocampus is
not unexpected because this region displays high speci¢c bind-
ing of radiolabelled NPY [33]. Furthermore, NPY mRNA
and peptide have been co-localised in the hippocampus of
chickens and Japanese quail [34]. Collectively, these ¢ndings
suggest that the functions of NPY in this brain region are
likely to have been conserved during evolution. The regula-
tory e¡ects of NPY in the chicken hippocampus have not
been elucidated. However, in mammals, interaction of NPY
with the Y2 receptor in the hippocampus has been implicated
in seizure modulation and in the facilitation of learning and
memory [35]. It is noteworthy that the pattern of Y2 receptor
expression within the hippocampus appears to di¡er between
birds and mammals. Thus, in the present study, Y2 receptor
mRNA was evenly distributed over the hippocampal region
whereas, in the rat, expression is limited to speci¢c sub-re-
gions, particularly CA2 and CA3 pyramidal cells and granule
cells [29,36]. The signi¢cance of this is unclear. However, a
di¡erence in the distribution pattern is predictable given that
the neuroanatomical organisation of the hippocampus di¡ers
markedly between birds and mammals to the extent that sub-
divisions applied to the mammalian structure are not recog-
nisable in birds [37].
In conclusion, we have cloned and characterised a chicken
NPY Y2 receptor and found considerable di¡erences in amino
acid sequence as well as pharmacological binding pro¢le. The
receptor appears to have a similar pattern of expression in the
brain as mammalian Y2. The sequence information obtained
from the chicken Y2 receptor should be of great importance
for achieving a greater understanding of the interactions be-
tween NPY as well as NPY-like ligands at the Y2 receptors.
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